Hopital Charles Lemoyne

Summary

Hopital Charles Lemoyne is a medical facility located in GREENFIELD PARK, Quebec. This center is recognized for care of Breast Cancer, Colorectal Cancer, Colon Cancer, Leukemia, Cancer and other specialties. Hopital Charles Lemoyne is involved with conducting 104 clinical trials across 124 conditions. There are 5 research doctors associated with this hospital, such as Pierre Desjardins, Melina Boutin, Selvan Rajakesari, and Timothy D. Lymberiou.

Top PIs

Clinical Trials running at Hopital Charles Lemoyne

Acute Myeloid Leukemia

Brain Tumor

Breast Cancer

Prostate Cancer

Colon Cancer

Acute Myelogenous Leukemia

Myelodysplastic Syndrome

Cervical Adenocarcinoma

Myeloproliferative Disorder

Acute Myeloid Leukemia or Myelodysplasia-Related Acute Myeloid Leukemia

Combination Therapies

for Acute Myeloid Leukemia

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the growth of cancer cells. Daunorubicin is a drug that blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Azacitidine is a drug that interacts with DNA to activate tumor-suppressing genes, resulting in an anti-tumor effect. Adding venetoclax to cytarabine and daunorubicin, and adding venetoclax to azacitidine, may work better than the usual treatment of cytarabine with daunorubicin alone. To decide if they are better, the study doctors are looking to see if venetoclax increases the rate of elimination of AML in participants by 20% or more compared to the usual approach.

Recruiting

1 award

Phase 2

6 criteria

Screening Tool

for Myeloid Cancer

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).

Recruiting

0 awards

Phase 2

1 criteria